

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/811,198	03/26/2004	Didier Communi	9409/2113B	2940
29933	7590 01/26/2006		EXAMINER	
PALMER & DODGE, LLP			LI, RUIXIANG	
	M. WILLIAMS GTON AVENUE		ART UNIT	PAPER NUMBER
BOSTON, M.	A 02199		1646	

DATE MAILED: 01/26/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	10/811,198	COMMUNI ET AL.	
Office Action Summary	Examiner	Art Unit	
	Ruixiang Li	. 1646	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with	the correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period or Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICA 36(a). In no event, however, may a rep will apply and will expire SIX (6) MONTH e, cause the application to become ABAI	ATION. y be timely filed S from the mailing date of this communication NDONED (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on This action is FINAL. 2b) ☑ This Since this application is in condition for allowa closed in accordance with the practice under E	s action is non-final. nce except for formal matter		is
Disposition of Claims			
4) ☐ Claim(s) 1-19 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-19 are subject to restriction and/or	wn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomplicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine 11.	epted or b) objected to by drawing(s) be held in abeyance tion is required if the drawing(s	e. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121	(d).
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Apprintly documents have been re u (PCT Rule 17.2(a)).	olication No eceived in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date		Mail Date rmal Patent Application (PTO-152)	

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-7, drawn to an antibody, classified in class 530, subclass 387.1.
 - II. Claims 8-9, 18, drawn to a method for determining whether an antibody can specifically bind to a receptor or a method of detecting the presence or a receptor on the surface of a cell, classified in class 435, subclass 7.1.
 - III. Claims 10-17, drawn to a method for determining whether an antibody is an agonist or antagonist of a receptor, classified in class 435, subclass 5.
 - IV. Claim 19, drawn to drawn to a method of diagnosing a predisposition to a disorder associated with the activity of a specific allele of a receptor, classified in class 435, subclass 6.
- 2. The inventions are distinct, each from the other for the following reasons. Inventions II-IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP §806.04, MPEP §808.01). In the instant case, the different inventions are drawn to completely different methods each having completely different method steps, using different compositions, and having completely different outcomes. Invention II requires determining the binding of an antibody to a receptor, Invention III requires measuring the receptor activity; whereas Invention IV reauires the use of nucleic acids for diagnosing. Each method is unique and not required another. Thus, all the methods are exclusive.

3. Invention I is related to Inventions II and III as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP§806.05 (h)). For example, an antibody may be used in a materially different process such as to purify a polypeptide that it binds.

Page 3

- 4. Invention I is related to Invention IV as distinct inventions. The different inventions are drawn to distinct product and method inventions because the product cannot be used in the methods.
- 5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 6. Because these inventions are distinct for the reasons given above and the search required for a single group is not required for any other group, restriction for examination purposes as indicated is proper.
- 7. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of

right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy. Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48 (b) if

Application/Control Number: 10/811,198 Page 5

Art Unit: 1646

one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48 (b) and by the fee required under 37

CFR 1.17 (I).

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875.

The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00

pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Brenda Brumback, can be reached on (571) 272-0961. The fax number for

the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for published

applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, please contact the Electronic

Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruidiang L.

Ruixiang Li, Ph.D.

Primary Examiner

January 22, 2006